GelMEDIX

GelMEDIX

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.gelmedix.com/

Last Round

Seed Round

Apr 30, 2026

Total Funding Raised

$34.73M

Momentum Score

25 /100

Company Overview

GelMEDIX is a biotechnology company developing therapies that restore vision loss by regenerating damaged retinal cells using a proprietary injectable hydrogel scaffold platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Advanced Materials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

injectable hydrogelcell therapy deliveryregenerative medicinehydrogel scaffoldGeographic Atrophyage-related macular degenerationdAMDlight-activated hydrogeldrug delivery platformgene therapy deliveryRPE cell therapybiomaterialstissue regenerationophthalmology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GelMEDIX Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

GelMEDIX Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Seed RoundApr 30, 2026
SeedFeb 17, 2026
VC RoundJan 8, 2026
SeedOct 20, 2025
DebtMar 26, 2024
Series A
Aug 9, 2022

Key People

Founding team and executive leadership

Max Cotler

Chief Executive Officer

Executive Team

Purnanand Sarma

Strategic Advisor Consulting CEO

Executive Team

GelMEDIX Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 30, 2026

    $747K raised in Seed Round.

  • Feb 17, 2026

    $13M round led by Safar Partners.

GelMEDIX Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GelMEDIX Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GelMEDIX's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range10
Year Founded2020
Last FundingApr 30, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.